Sydney 2005:
Role of the IGF-1/IGF-1 Receptor Pathway in the 5TMM Experimental Mouse Model

By IMF Admin on June 30, 2011 7:51 AM | No Comments

Wowza Media Test Article For iOS

By IMF Admin on June 28, 2011 1:26 PM | No Comments

Wowza Media Test Article For iOS

Advocacy Update - February 28, 2011

By IMF Admin on June 27, 2011 10:42 AM | No Comments

Advocacy Update - February 28, 2011

Kongressbericht: Symposium ?Das Multiple Myelom 2006: auf dem Weg zur Heilung??

By IMF Admin on June 26, 2011 4:27 PM | No Comments

Kongressbericht: Symposium ?Das Multiple Myelom 2006: auf dem Weg zur Heilung??

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma

By IMF Admin on June 25, 2011 12:32 AM | No Comments

Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma

RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients

By IMF Admin on June 25, 2011 12:32 AM | No Comments

RT-PCR Amplicons in the Plasma of Multiple Myeloma Patients

Step-by-Step Nutrition Action Plans

By IMF Admin on June 24, 2011 8:57 AM | No Comments

Step-by-Step Nutrition Action Plans

THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA

By IMF Admin on June 21, 2011 1:05 AM | No Comments

THE INTERNATIONAL MYELOMA FOUNDATION IDENTIFIES POTENTIAL LINK BETWEEN GENETIC PATHWAYS AND ENVIRONMENTAL RISKS FOR MYELOMA

??? ???????? ???????? - ???????, ???????

By IMF Admin on June 19, 2011 10:30 PM | No Comments

??? ???????? ???????? - ???????, ???????

Pilot Study Evaluating the Safety & Efficacy of AMD3100 ...

By IMF Admin on June 19, 2011 3:40 AM | No Comments

Pilot Study Evaluating the Safety & Efficacy of AMD3100 ...

ASCO 2006

By IMF Admin on June 16, 2011 10:03 AM | No Comments

ASCO 2006

What's New In Research - February 12, 2004

By IMF Admin on June 15, 2011 3:24 AM | No Comments

What's New In Research - February 12, 2004

Myeloma Matrix VELCADE® Supplement

By IMF Admin on June 15, 2011 3:24 AM | No Comments

Myeloma Matrix VELCADE® Supplement

Phase III THALOMID® Clinical Trials

By IMF Admin on June 13, 2011 2:13 PM | No Comments

Phase III THALOMID® Clinical Trials

Phase II THALOMID® Clinical Trials

By IMF Admin on June 13, 2011 1:52 PM | No Comments

Phase II THALOMID® Clinical Trials

Myelom Merkur - August 2007

By IMF Admin on June 11, 2011 10:13 AM | No Comments

Myelom Merkur - August 2007

ASCO 2006

By IMF Admin on June 11, 2011 9:55 AM | No Comments

ASCO 2006

Myelom Merkur - September 2009

By IMF Admin on June 11, 2011 9:44 AM | No Comments

Myelom Merkur - September 2009

Mensajero del Mieloma
Seminario en Valencia para pacientes y sus familias
S

By IMF Admin on June 11, 2011 7:32 AM | No Comments

Mensajero del Mieloma
Seminario en Valencia para pacientes y sus familias
S

Myelom Merkur - Mai 2008

By IMF Admin on June 11, 2011 6:54 AM | No Comments

Myelom Merkur - Mai 2008

Myeloma Merkur - Dezember 2008

By IMF Admin on June 11, 2011 5:11 AM | No Comments

Myeloma Merkur - Dezember 2008

Myelom Merkur - 5. Ausgabe, January 2007

By IMF Admin on June 11, 2011 4:09 AM | No Comments

Myelom Merkur - 5. Ausgabe, January 2007

Myelom Merkur - Ausgabe, November 2006

By IMF Admin on June 11, 2011 3:49 AM | No Comments

Myelom Merkur - Ausgabe, November 2006

Myelom Merkur - 3. Ausgabe, April 2007

By IMF Admin on June 11, 2011 3:45 AM | No Comments

Myelom Merkur - 3. Ausgabe, April 2007

Myelom Merkur - Mai 2010

By IMF Admin on June 11, 2011 3:38 AM | No Comments

Myelom Merkur - Mai 2010

Myelom Merkur - Ausgabe, August 2006

By IMF Admin on June 11, 2011 3:30 AM | No Comments

Myelom Merkur - Ausgabe, August 2006

Myelom Merkur - Juli 2008

By IMF Admin on June 11, 2011 3:08 AM | No Comments

Myelom Merkur - Juli 2008

Myelom Merkur - Juni 2009

By IMF Admin on June 11, 2011 3:06 AM | No Comments

Myelom Merkur - Juni 2009

Myelom Merkur - October 2010

By IMF Admin on June 11, 2011 1:24 AM | No Comments

Myelom Merkur - October 2010

Myeloma Minute
December 17, 2008

By IMF Admin on June 10, 2011 9:10 PM | No Comments

Myeloma Minute
December 17, 2008

A Dra. Hungr

By IMF Admin on June 10, 2011 9:09 PM | No Comments

A Dra. Hungr

Y.C. Chen, MD

By IMF Admin on June 10, 2011 9:02 PM | No Comments

Y.C. Chen, MD

La International Myeloma Foundation indique que la recommandation d'autorisation de mise sur le march

By IMF Admin on June 10, 2011 9:02 PM | No Comments

La International Myeloma Foundation indique que la recommandation d'autorisation de mise sur le march

Una explicaci

By IMF Admin on June 10, 2011 9:02 PM | No Comments

Una explicaci

Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy

By IMF Admin on June 10, 2011 9:00 PM | No Comments

Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy

Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma

By IMF Admin on June 10, 2011 9:00 PM | No Comments

Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma

Está usted o alguien que usted ama luchando contra el mieloma mýltiple?

By IMF Admin on June 10, 2011 8:58 PM | 2 Comments

Está usted o alguien que usted ama luchando contra el mieloma mýltiple?

ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II ?Bologna 2002? Study

By IMF Admin on June 10, 2011 8:58 PM | No Comments

ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II ?Bologna 2002? Study

Elijah Alexander: ASH 2007: A Patient's Perspective

By IMF Admin on June 10, 2011 8:57 PM | No Comments

Elijah Alexander: ASH 2007: A Patient's Perspective

La Fondation Internationale du My

By IMF Admin on June 10, 2011 8:54 PM | No Comments

La Fondation Internationale du My

Revue de la Maladie et des Options Therapeutiques

By IMF Admin on June 10, 2011 8:53 PM | No Comments

Revue de la Maladie et des Options Therapeutiques

ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

By IMF Admin on June 10, 2011 8:51 PM | No Comments

ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients

ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma

By IMF Admin on June 10, 2011 8:49 PM | No Comments

ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma

ASH 2009: Martin Ellis
Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity

By IMF Admin on June 10, 2011 8:48 PM | 3 Comments

ASH 2009: Martin Ellis
Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity

Dr. Robert Kyle - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007

By IMF Admin on June 10, 2011 8:48 PM | No Comments

Dr. Robert Kyle - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007

Conociendo Dexametasona y Otros Esteroides

By IMF Admin on June 10, 2011 8:48 PM | No Comments

Conociendo Dexametasona y Otros Esteroides

Nouvelles d'ASH 2009

By IMF Admin on June 10, 2011 8:47 PM | No Comments

Nouvelles d'ASH 2009

Celgene?s Revlimid

By IMF Admin on June 10, 2011 8:45 PM | No Comments

Celgene?s Revlimid

A PATIENT ADVOCACY COALITION LED BY THE INTERNATIONAL MYELOMA FOUNDATION AND THE MDS FOUNDATION SAYS ITS CANCER PATIENT STATEMENT OF PRINCIPLES GAINS MOMENTUM GOING INTO THE ASH CANCER CONFERENCE

By IMF Admin on June 10, 2011 8:45 PM | No Comments

A PATIENT ADVOCACY COALITION LED BY THE INTERNATIONAL MYELOMA FOUNDATION AND THE MDS FOUNDATION SAYS ITS CANCER PATIENT STATEMENT OF PRINCIPLES GAINS MOMENTUM GOING INTO THE ASH CANCER CONFERENCE

Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma

By IMF Admin on June 10, 2011 8:41 PM | No Comments

Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma

Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma

By IMF Admin on June 10, 2011 8:41 PM | No Comments

Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma

ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial

By IMF Admin on June 10, 2011 8:37 PM | No Comments

ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial

The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.

By IMF Admin on June 10, 2011 8:35 PM | No Comments

The International Myeloma Foundation, the MDS Foundation and a Coalition of Patient Advocacy Organizations Call for Updated Rules for Reimbursement, Access and Approvals for New and Existing Cancer Treatments.

Dr. Beksac - ASH 2007 G

By IMF Admin on June 10, 2011 8:35 PM | No Comments

Dr. Beksac - ASH 2007 G

Everyone Makes a Difference!

By IMF Admin on June 10, 2011 8:34 PM | No Comments

Everyone Makes a Difference!

Advocacy Update - June 21, 2010

By IMF Admin on June 10, 2011 8:34 PM | No Comments

Advocacy Update - June 21, 2010

Take the IMF's Support Group Challenge

By IMF Admin on June 10, 2011 8:22 PM | No Comments

Take the IMF's Support Group Challenge

Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients

By IMF Admin on June 10, 2011 8:19 PM | No Comments

Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients

ASH 2006 Highlights for Patients with Myeloma

By IMF Admin on June 10, 2011 8:19 PM | No Comments

ASH 2006 Highlights for Patients with Myeloma

Myeloma Minute
February 5, 2009

By IMF Admin on June 10, 2011 8:18 PM | No Comments

Myeloma Minute
February 5, 2009

VELCADE® Adds Long-Term Overall Survival Benefit to Label

By IMF Admin on June 10, 2011 8:16 PM | No Comments

VELCADE® Adds Long-Term Overall Survival Benefit to Label

Tributes and Memorials

By IMF Admin on June 10, 2011 8:15 PM | No Comments

Tributes and Memorials

An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma

By IMF Admin on June 10, 2011 8:14 PM | No Comments

An Interim Analysis of Velcade/Dexamethasone vs VAD as Induction Therapy Prior to Transplant in Newly Diagnosed Myeloma

Jamie Cavanagh, St. Bartholomew's Hospital, London, UK

By IMF Admin on June 10, 2011 8:13 PM | No Comments

Jamie Cavanagh, St. Bartholomew's Hospital, London, UK

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma

By IMF Admin on June 10, 2011 8:11 PM | No Comments

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma

IMFer Profile

By IMF Admin on June 10, 2011 8:09 PM | No Comments

IMFer Profile

ASH 2009: Sundar Jagannath, Overview

By IMF Admin on June 10, 2011 8:04 PM | No Comments

ASH 2009: Sundar Jagannath, Overview

INTERNATIONAL MYELOMA FOUNDATION (IMF): STUDI MULTIPLI PRESENTATI IN OCCASIONE DELLA CONFERENZA MONDIALE SUL CANCRO INDICANO NUOVE TERAPIE CHE CAMBIANO LA PROSPETTIVA PER I PAZIENTI AFFETTI DA NEOPLASIE EMATOLOGICHE

By IMF Admin on June 10, 2011 8:04 PM | No Comments

INTERNATIONAL MYELOMA FOUNDATION (IMF): STUDI MULTIPLI PRESENTATI IN OCCASIONE DELLA CONFERENZA MONDIALE SUL CANCRO INDICANO NUOVE TERAPIE CHE CAMBIANO LA PROSPETTIVA PER I PAZIENTI AFFETTI DA NEOPLASIE EMATOLOGICHE

ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan?Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan?Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years? Follow-up and Extensive Subseq

By IMF Admin on June 10, 2011 8:02 PM | No Comments

ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan?Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan?Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years? Follow-up and Extensive Subsequent Therapy Use

ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study

By IMF Admin on June 10, 2011 8:01 PM | No Comments

ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study

ASH2009: Bank On A Cure

By IMF Admin on June 10, 2011 8:00 PM | No Comments

ASH2009: Bank On A Cure

Multiple Musicians Against Multiple Myeloma

By IMF Admin on June 10, 2011 8:00 PM | No Comments

Multiple Musicians Against Multiple Myeloma

Myeloma Minute - November 21, 2007

By IMF Admin on June 10, 2011 7:59 PM | No Comments

Myeloma Minute - November 21, 2007

Un resumen de las presentaciones de ASH 2009

By IMF Admin on June 10, 2011 7:58 PM | No Comments

Un resumen de las presentaciones de ASH 2009

Clinically relevant end points and new drug approvals for myeloma

By IMF Admin on June 10, 2011 7:54 PM | No Comments

Clinically relevant end points and new drug approvals for myeloma

Olympic Spirit

By IMF Admin on June 10, 2011 7:53 PM | No Comments

Olympic Spirit

Getting Involved

By IMF Admin on June 10, 2011 7:53 PM | 1 Comment

Getting Involved

ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis

By IMF Admin on June 10, 2011 7:53 PM | No Comments

ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis

Advocacy Update - February 15, 2010

By IMF Admin on June 10, 2011 7:53 PM | No Comments

Advocacy Update - February 15, 2010

ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma

By IMF Admin on June 10, 2011 7:51 PM | No Comments

ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma

ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity

By IMF Admin on June 10, 2011 7:48 PM | No Comments

ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity

Discussione - 3

By IMF Admin on June 10, 2011 7:47 PM | No Comments

Discussione - 3

ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD

By IMF Admin on June 10, 2011 7:47 PM | No Comments

ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD

Problemi legati alla terapia

By IMF Admin on June 10, 2011 7:46 PM | No Comments

Problemi legati alla terapia

ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study

By IMF Admin on June 10, 2011 7:46 PM | No Comments

ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study

ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin

By IMF Admin on June 10, 2011 7:45 PM | No Comments

ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin

ASH 2006 Multiple Myeloma Highlights for Physicians

By IMF Admin on June 10, 2011 7:45 PM | No Comments

ASH 2006 Multiple Myeloma Highlights for Physicians

Tandem vs Single Transplant: Which is Better for Whom?

By IMF Admin on June 10, 2011 7:44 PM | No Comments

Tandem vs Single Transplant: Which is Better for Whom?

ASH 2005 Webcast - Effect Of Velcade Therapy On Markers Of Bone Resorption

By IMF Admin on June 10, 2011 7:43 PM | No Comments

ASH 2005 Webcast - Effect Of Velcade Therapy On Markers Of Bone Resorption

ASH 2009: Herv

By IMF Admin on June 10, 2011 7:42 PM | No Comments

ASH 2009: Herv

ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy

By IMF Admin on June 10, 2011 7:41 PM | No Comments

ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy

Myeloma Minute
February 10, 2008

By IMF Admin on June 10, 2011 7:41 PM | No Comments

Myeloma Minute
February 10, 2008

ASH 2005 Webcast - Combination Therapy With Melphalan, Prednisone and Thalidomide

By IMF Admin on June 10, 2011 7:39 PM | No Comments

ASH 2005 Webcast - Combination Therapy With Melphalan, Prednisone and Thalidomide

ASH 2005 Webcast - Combination Therapy With Thalidomide, Velcade And Dexamethasone

By IMF Admin on June 10, 2011 7:39 PM | No Comments

ASH 2005 Webcast - Combination Therapy With Thalidomide, Velcade And Dexamethasone

ASH 2005 Webcast - Stem Cell Harvesting Using GCSF Alone

By IMF Admin on June 10, 2011 7:39 PM | No Comments

ASH 2005 Webcast - Stem Cell Harvesting Using GCSF Alone

ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM

By IMF Admin on June 10, 2011 7:31 PM | No Comments

ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)

ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

By IMF Admin on June 10, 2011 7:31 PM | No Comments

ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma

By IMF Admin on June 10, 2011 7:30 PM | No Comments

Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma

ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities

By IMF Admin on June 10, 2011 7:30 PM | No Comments

ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities

ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients

By IMF Admin on June 10, 2011 7:28 PM | No Comments

ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients

MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study

By IMF Admin on June 10, 2011 7:27 PM | No Comments

MP versus MPT in elderly myeloma patients: the final outcome of the HOVON 49 study

A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop

By IMF Admin on June 10, 2011 7:27 PM | No Comments

A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop

By IMF Admin on June 10, 2011 7:27 PM | No Comments

A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop

ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients

By IMF Admin on June 10, 2011 7:26 PM | No Comments

ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients

ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib?Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial

By IMF Admin on June 10, 2011 7:24 PM | No Comments

ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib?Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial

ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma

By IMF Admin on June 10, 2011 7:24 PM | No Comments

ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma

ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients

By IMF Admin on June 10, 2011 7:22 PM | No Comments

ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients

ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)

By IMF Admin on June 10, 2011 7:21 PM | No Comments

ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)

Update From ASCO 2004: Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN

By IMF Admin on June 10, 2011 7:20 PM | No Comments

Update From ASCO 2004: Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN

Update from ASH 2009:
Novel Agents

By IMF Admin on June 10, 2011 7:19 PM | No Comments

Update from ASH 2009:
Novel Agents

Advocacy Update - August 31, 2010

By IMF Admin on June 10, 2011 7:17 PM | No Comments

Advocacy Update - August 31, 2010

The Importance of Voting on November 2nd

By IMF Admin on June 10, 2011 7:17 PM | No Comments

The Importance of Voting on November 2nd

Международный фонд борьбы с миеломой заяk

By IMF Admin on June 10, 2011 7:15 PM | No Comments

Международный фонд борьбы с миеломой заявляет о том, что рекомендация одобрить REVLIMID(R) может помочь больным во всей Европе

Issues of importance to patients are getting lost in partisan battles in Congress. Get involved!

By IMF Admin on June 10, 2011 7:13 PM | No Comments

Issues of importance to patients are getting lost in partisan battles in Congress. Get involved!

ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

By IMF Admin on June 10, 2011 7:13 PM | No Comments

ASCO 2010: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

News & Notes - Spring 2000

By IMF Admin on June 10, 2011 10:40 AM | No Comments

News & Notes - Spring 2000

Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma in Patients with Elevated Baseline Serum Creatinine

By IMF Admin on June 10, 2011 10:40 AM | No Comments

Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma in Patients with Elevated Baseline Serum Creatinine

Phase II/III THALOMID® Clinical Trials

By IMF Admin on June 8, 2011 4:05 PM | No Comments

Phase II/III THALOMID® Clinical Trials

Advocacy Update - September 1, 2009

By IMF Admin on June 8, 2011 2:57 PM | No Comments

Advocacy Update - September 1, 2009

THE INTERNATIONAL MYELOMA FOUNDATION, MARKING 20 YEARS OF SERVING THE MYELOMA COMMUNITY, APPLAUDS MEMBERS OF THE INTERNATIONAL MYELOMA WORKING GROUP FOR THEIR BODY OF WORK BEING PRESENTED AT THE ASH HEMATOLOGY CONFERENCE

By IMF Admin on June 7, 2011 7:12 PM | No Comments

THE INTERNATIONAL MYELOMA FOUNDATION, MARKING 20 YEARS OF SERVING THE MYELOMA COMMUNITY, APPLAUDS MEMBERS OF THE INTERNATIONAL MYELOMA WORKING GROUP FOR THEIR BODY OF WORK BEING PRESENTED AT THE ASH HEMATOLOGY CONFERENCE

Advocacy Update
August 5, 2010

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Advocacy Update
August 5, 2010

Patient Perspective: Cancer Etiquette

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Patient Perspective: Cancer Etiquette

Bank On A Cure

By IMF Admin on June 7, 2011 7:12 PM | 3 Comments

Bank On A Cure

INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS

By IMF Admin on June 7, 2011 7:12 PM | No Comments

INDEPENDENT SURVEY RATES THE INTERNATIONAL MYELOMA FOUNDATION THE #1 RESOURCE FOR PATIENTS

Ferreting for Facts in the Realm of Clinical Trials

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Ferreting for Facts in the Realm of Clinical Trials

Message from the IMF President

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Message from the IMF President

Spring 2006 Myeloma Today in PDF

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Spring 2006 Myeloma Today in PDF

Advocacy Update: Federal Support for Cancer Issues in Decline

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Advocacy Update: Federal Support for Cancer Issues in Decline

Watch a Short Video About the IMF

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Watch a Short Video About the IMF

Dorotea Fantl, MD

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Dorotea Fantl, MD

Myeloma Manager™
Personal Care Assistant™ Version 4.0.2

By IMF Admin on June 7, 2011 7:12 PM | 8 Comments

Myeloma Manager™
Personal Care Assistant™ Version 4.0.2

Freie Leichtketten-Tests verstehen

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Freie Leichtketten-Tests verstehen

Dr. Palumbo - A Phase III Study Evaluating the Efficacy and Safety of Lenalidomide Combined With Melphalan and Prednisone in Patients ? 65 Years With Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide vs Fixed-Duration Regimens

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Dr. Palumbo - A Phase III Study Evaluating the Efficacy and Safety of Lenalidomide Combined With Melphalan and Prednisone in Patients ? 65 Years With Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide vs Fixed-Duration Regimens

Myeloma Quilt of Courage #1 - Susan Cann

By IMF Admin on June 7, 2011 7:12 PM | No Comments

Myeloma Quilt of Courage #1 - Susan Cann

THE INTERNATIONAL MYELOMA FOUNDATION SAYS PREVIOUSLY UNTREATED PATIENTS COULD BENEFIT FROM FDA APROVAL OF VELCADE® FOR 'FRONT-LINE' USE